CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
26 avr. 2024 08h00 HE
|
CG Oncology Inc.
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
25 avr. 2024 16h05 HE
|
Cardiff Oncology, Inc.
- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
25 avr. 2024 08h45 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
24 avr. 2024 10h00 HE
|
CG Oncology Inc.
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
23 avr. 2024 13h42 HE
|
Novartis Pharma AG
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic...
[Latest] Global 3D Cell Culture Market Size/Share Worth USD 4.6 Billion by 2033 at a 11.3% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
18 avr. 2024 12h30 HE
|
Custom Market Insights
Austin, TX, USA, April 18, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “3D Cell Culture Market Size, Trends and Insights By Product (Scaffolds Based 3d...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
18 avr. 2024 08h45 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., April 18, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects.
17 avr. 2024 10h15 HE
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most...
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
17 avr. 2024 08h00 HE
|
Evaxion Biotech
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosingFavorable safety profile confirmedTrial on track for one-year clinical efficacy readout in Q3...
Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort
15 avr. 2024 16h09 HE
|
Imugene Limited
Imugene opened enrollment for its CF-33 (VAXINIA) expansion study in bile tract cancer (cholangiocarcinoma) patients.